A BiPAP in spontaneous mode follows the patient. The machine delivers IPAP when the patient triggers a breath and EPAP when they exhale, and if the patient stops breathing, the machine also waits. For most obstructive sleep apnea patients that is exactly right — the airway is the problem, not the respiratory drive. But for patients whose respiratory drive is the problem, the machine needs to take over at a defined rate when the patient fails to breathe. That mode is BiPAP-ST (spontaneous-timed): the machine responds to patient-triggered breaths when they happen, and delivers machine-timed breaths when they do not. The “T” is a backup rate, measured in breaths per minute.
This article covers the clinical indications for BiPAP-ST, how titration works, and a practical review of ST-capable devices in the Indian market with pricing.
What BiPAP-ST adds over BiPAP-S
BiPAP-S delivers two pressures but no backup rate. If the patient stops breathing for any reason — a central apnea, a prolonged expiratory pause, a swallowing event, a seizure — the machine does not initiate a breath. BiPAP-ST adds a backup rate, typically set at 12–18 breaths per minute. If the patient has not triggered a breath within the backup-rate interval (e.g., 60 ÷ 12 = 5 seconds for a rate of 12), the machine delivers a machine-timed breath at the IPAP level, held for a clinician-set inspiratory time, then releases to EPAP for expiration.
The machine continues to accept patient-triggered breaths whenever the patient initiates them. The backup rate is a floor — if the patient’s spontaneous rate is above the backup rate, the patient effectively runs the machine. If the patient’s spontaneous rate falls below, the machine takes over.
This is the architectural step toward non-invasive ventilation proper: a BiPAP-ST is, functionally, a pressure-targeted non-invasive ventilator operating in a pressure-support-with-backup mode. For many patients it is clinically indistinguishable from a full home ventilator for the same indication.
When BiPAP-ST is indicated
Central sleep apnea not responsive to CPAP
The first-line treatment for central sleep apnea in most patients is optimisation of the underlying cause (heart failure in Cheyne-Stokes, opioids in drug-induced central apnea, altitude acclimatisation if relevant). If the central apnea persists and a positive-pressure intervention is warranted, CPAP is tried first — about half of central apnea responds to CPAP alone. For those who don’t respond, BiPAP-ST is the next step in patients who are not HFrEF-with-LVEF-45% or below (in whom ASV is contraindicated — see the heart failure article).
The backup rate in BiPAP-ST overrides the central apnea by initiating a breath whenever the patient fails to. Over time, with the central apnea events suppressed, some patients stabilise and the backup rate is triggered less frequently. The mode is stable and well-tolerated in most patients.
Severe neuromuscular disease
Progressive respiratory muscle weakness — ALS, muscular dystrophies, post-polio syndrome, myasthenia gravis with nocturnal ventilatory failure — produces a clinical picture where the patient cannot reliably sustain an adequate rate and volume without mechanical assistance. BiPAP-ST is a standard intermediate step before full home mechanical ventilation in many of these patients. (ATS/ERS statement)
For ALS specifically, home NIV is a standard-of-care intervention from the point of documented respiratory muscle weakness (FVC < 50% predicted, or symptomatic nocturnal ventilatory failure with lower FVC thresholds for bulbar-predominant disease). BiPAP-ST with volume-assurance (iVAPS/AVAPS) is often preferred — see the TVAPS article — but BiPAP-ST without volume assurance remains appropriate for many patients and is materially cheaper.
Chest wall and restrictive disease
Severe kyphoscoliosis, post-tuberculous fibrothorax with diaphragmatic impairment, and post-thoracoplasty states can produce a similar picture: reduced vital capacity, chronic hypercapnia, and nocturnal ventilatory failure. BiPAP-ST is appropriate, usually with inspiratory time extended to compensate for the restricted chest excursion.
Pediatric central apnea (off-label)
Congenital central hypoventilation syndrome and some forms of pediatric central apnea are managed with BiPAP-ST or — more commonly — with a pediatric-labelled home ventilator. BiPAP-ST use in children is generally off-label on adult-marketed devices, and pediatric centres typically use dedicated pediatric NIV equipment. If a pediatric patient is to be managed on a BiPAP-ST device, it should be under specialist pediatric pulmonology supervision with appropriate pediatric interface and pressure-range settings.
Chronic hypercapnic COPD (selected)
A specific subset — stable severe COPD with persistent daytime hypercapnia (PaCO₂ > 50 mmHg) and history of recurrent hypercapnic exacerbations — benefits from home NIV, often with BiPAP-ST or with TVAPS if available. The backup rate matters here because these patients have a partly depressed ventilatory drive from chronic hypercapnia. (Murphy PB et al, JAMA 2017)
How titration works
A BiPAP-ST titration is substantively more complex than a CPAP titration. The clinician sets:
- IPAP — inspiratory pressure. Start at 10–12 cmH₂O for an adult, titrate up based on adequacy of ventilation (tidal volume, CO₂ response). Typical range 12–20 cmH₂O.
- EPAP — expiratory pressure. Sufficient to maintain upper-airway patency if OSA coexists (5–10 cmH₂O), or lower if the indication is purely central or purely neuromuscular.
- Backup rate — 12–16 breaths per minute for most indications. Higher (16–20) in advanced NMD or some central hypoventilation. Should be set slightly below the patient’s natural rate so spontaneous breaths predominate.
- Inspiratory time (Ti) — typical 1.0–1.4 seconds for adults. Longer in restrictive chest wall disease; shorter in obstructive physiology.
- Rise time — how fast IPAP is reached from EPAP. Faster (50–100 ms) for NMD patients who fatigue; slower (300–600 ms) for comfort in non-urgent indications.
- Trigger and cycle sensitivity — how readily the device responds to the patient’s inspiratory effort and when it transitions from IPAP to EPAP. Set to minimise patient-ventilator asynchrony.
Verification is done with overnight oximetry at minimum, preferably with transcutaneous CO₂ (tcCO₂) monitoring to confirm that ventilation is actually adequate. A morning capillary or arterial blood gas the day after titration is the reference.
Follow-up is essential: at 1 month, 3 months, and 6 months post-initiation. Titrations are rarely optimal on the first attempt, and patient tolerance of settings often evolves.
BiPAP-ST devices in the Indian market
A representative selection of BiPAP-ST-capable devices available in India with typical 2026 pricing. Prices vary by distributor, region, and whether humidifier and heated tubing are bundled.
| Device | Mode capability | Pressure range | Typical price (INR) | Notes |
|---|---|---|---|---|
| ResMed AirCurve 10 ST | BiPAP S, ST, auto | 4–25 cmH₂O | 1,80,000–2,30,000 | Mature algorithm, strong AirView cloud ecosystem, widely serviced in metros |
| ResMed Lumis 100 VPAP ST | BiPAP S, ST | 4–30 cmH₂O | 2,00,000–2,50,000 | Higher-end than AirCurve for home-ventilation-segment; iVAPS available on Lumis VPAP ST-A variant |
| Philips DreamStation BiPAP Auto (with ST capability) | BiPAP S, Auto S, ST | 4–25 cmH₂O | 1,70,000–2,20,000 | SD-card data download, wide Indian distribution |
| Philips DreamStation BiPAP AVAPS | BiPAP S, ST, AVAPS | 4–25 cmH₂O | 1,90,000–2,40,000 | Adds volume-assurance; appropriate for hypercapnic indications |
| BMC Y30T | BiPAP S, ST | 4–25 cmH₂O | 1,10,000–1,50,000 | Budget-leaning, extensive Indian distribution, algorithm less validated in independent literature |
| Home Medix HM-BV-30 | BiPAP S, ST, TVAPS | 4–30 cmH₂O | 1,30,000–1,70,000 | Regional availability; verify service network in your location |
| BPL LifePap 25 STa | BiPAP S, ST, auto | 4–25 cmH₂O | 1,00,000–1,35,000 | Indian manufacturer; price-sensitive segment; service network limited to BPL distributors |
| Oxymed BiPAP i-Series P1 | BiPAP S, ST | 4–25 cmH₂O | 85,000–1,20,000 | Budget tier; generic ST algorithm; limited peer-reviewed validation |
The price tiers reflect three categories: premium (ResMed, Philips) at ₹1.7–2.5 lakh with mature algorithms and cloud ecosystems; mid-tier (BMC, Home Medix) at ₹1.1–1.7 lakh with functional ST modes and variable algorithm validation; and budget (BPL, Oxymed and similar) at ₹0.8–1.4 lakh, where feature-compliance is present but algorithm behaviour in edge cases is less well characterised.
For a straightforward BiPAP-ST indication in a stable patient — for example, CPAP-non-responsive central apnea in a non-HFrEF patient, or moderate NMD without hypercapnia — a mid-tier or premium device is appropriate. For more complex indications (significant hypercapnia, rapidly progressive NMD, pediatric use), premium devices with mature algorithms and cloud monitoring are strongly preferred; the incremental cost is justified by the lower risk of algorithm-related therapy gaps.
A note on prescribing in India
BiPAP-ST prescriptions in India are concentrated at specialist centres. General practitioners and even some pulmonologists rarely initiate ST-mode therapy without a sleep-medicine or home-ventilation consultation. The right path is:
- Sleep study (in-lab PSG with full respiratory montage, preferably with transcutaneous CO₂) establishing the mode indication.
- In-lab titration to set the starting IPAP/EPAP/rate/Ti.
- Device procurement from a distributor who can service it locally — important because home ventilators benefit from same-city service for rapid fault resolution.
- Home setup with a respiratory therapist visit to confirm mask fit, humidification, tube setup, and data-download process.
- Follow-up at 30 days minimum with overnight oximetry data and, if available, tcCO₂ or morning blood gas.
Short-cutting this pathway — which happens commonly, especially in smaller Indian cities where specialist sleep-medicine access is limited — produces patients whose titration is wrong, whose adherence is poor, and whose mortality benefit from home NIV is not being realised.
The bottom line
BiPAP-ST is a clinically distinct mode from BiPAP-S. The backup rate is not a comfort feature; it is a therapeutic lever that matters for a defined set of indications: central apnea not responsive to CPAP, neuromuscular disease, restrictive chest wall disease, selected chronic hypercapnic COPD, and pediatric central hypoventilation. For those indications, device selection should weigh algorithm maturity and local service availability heavily; budget machines are appropriate only when the clinical picture is stable and the titration is confident.
Consult your pulmonologist or sleep physician for BiPAP-ST prescription and titration. This article is educational and not a substitute for individual clinical decision-making.
References: ATS/ERS statement on NIV in neuromuscular disease; Bourke et al, Lancet Neurol 2006; Murphy et al, JAMA 2017; Köhnlein et al, Lancet Respir Med 2014; AASM practice parameters on BiPAP-ST titration; individual device manufacturer technical documentation [CITATION].